Faculty

Institution

Unit

Venue

Thomas McFall

Assistant Professor

Medical College of Wisconsin

Affiliations

Biochemistry

Graduate School

Pancreatic Cancer Program

Thomas Mcfall is currently serving as a Biochemistry Assistant Professor at Medical College of Wisconsin.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Thomas McFall

Medical College of Wisconsin

Assistant Professor

You can click a keyword to filter the displayed items

oncology medicinal research cancer research pharmacology oncogenes tumor biology cancer biology molecular cancer tumor targeting cell biology enzyme inhibition cancer treatment urology cancer care cellular therapy cancer immunotherapy gynecologic oncology cancer genomics pancreatic cancer genetics gene expression breast cancer prostate cancer protein science endocrine oncology cancer genetics receptors cancer cells anti-cancer agents colorectal cancer biological chemistry cell death drug targeting signaling pathways therapeutic efficacy gastrointestinal oncology receptor tyrosine kinases progesterone receptor clinical biochemistry leukemia tumor suppressors endocrine research wild-type ras-gtp tumor-selective disruption androgen receptor function nucleic acids experimental medicine medical mycology allelic variant mutagenesis short-term variability oncologic imaging benchmark studies genitourinary cancers transcriptomics technology translational bioinformatics precision medicine cellular senescence localized excited state chronic inflammation in vivo systems science studies inhibitory activity clinical pharmacology systems mechanism luminal breast cancer promotes invasiveness critical micrornas glucocorticoid receptor status principal determinant pancreatic ductal adenocarcinoma androgen receptor levels hybrid enzalutamide derivatives inhibit viability amino-terminal domain sustained gene activation carcinogenesis cancer therapy synthetic lethality estrogen receptor

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract B008: Ex-Vivo Organotypic Tumor Model of Metastatic Core Biopsy Serve as a Pragmatic Platform for Real-Time Personalized Therapy in Pancreatic Adenocarcinoma. Cancer Research (2025)

metastasispathologyradiation oncologyabstract b008metastatic core biopsysurgical oncologyradiologycancer imagingcancer researchreal-time personalized therapypancreatic cancerpancreatic surgeryoncology

Mathematical Modeling Suggests 14-3-3 Proteins Modulate Raf Paradoxical Activation. PLoS Computational Biology (2025)

molecular and cellular biologyprotein sciencecell signalingprotein functionmolecular cell biologymolecular biologybiological chemistrybiomolecular interactionssignal transduction14-3-3 proteins

Mek Inhibitor-Based Therapy in Metastatic Pancreatic Adenocarcinoma With Kras G12R Alteration.. Journal of Clinical Oncology (2025)

Elizabeth AuckleyGrace YingStephanie YohayMohammed AldakkakSamih Z ThaljiParnian VakiliJustin GrahlBradley MayerFaisal ShahjehanSoon Khai LowDouglas B. EvansKathleen K. ChristiansYongwoo David SeoBeth EricksonWilliam Adrian HallThomas McFallRazelle KurzrockBen GeorgeMandana Kamgar

immunologycancer discoverypharmacologytherapeutic targetstumor biologynovel therapiescancer researchpancreatic cancercancer cellscancer treatmentoncogenesmedicinal researchcellular therapysystems biologymetastasistumor targetingmek inhibitor-based therapytreatment developmentmetastatic pancreatic adenocarcinomaoncology

Pancreatic Cells Are Resistant to Krasq61L Expression Due to Hyperactive Erk/Mapk Signaling and Apoptosis Induction. Cancer Research Communications (2025)

molecular and cellular biologyoncogenesreceptor tyrosine kinasestumor biologyapoptosispancreatic cellshyperactive erk/mapk signalingcell deathcell signalingimmunologycell biologymolecular cancersignaling pathwayspancreatic cancermolecular gastroenterologyapoptosis inductionsignal transduction

Chemotherapy-Free Treatment Targeting Fusions and Driver Mutations in Kras Wild-Type Pancreatic Ductal Adenocarcinoma, a Case Series. Therapeutic Advances in Medical Oncology (2024)

Maahum MehdiAniko SzaboAditya ShreenivasJames P. ThomasSusan TsaiKathleen K. ChristiansDouglas B. EvansCallisia N. ClarkeWilliam A. HallBeth EricksonGulrayz AhmedBicky ThapaThomas McFallBen GeorgeRazelle KurzrockMandana Kamgar

chemotherapy-free treatmentpancreatic cancermedicinedriver mutationsoncology

Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Gastroenterology (2024)

Ben GeorgeOlga KudryashovaAndrey KravetsSamih ThaljiSubramaniam MalarkannanRazelle KurzrockEkatherina ChernyavskayaMariia GusakovaDmitry KravchenkoDmitry TychininEgor SavinLolita AlekseevaAnna ButusovaAleksander BagaevNara ShinJessica H. BrownIsha SethiDandan WangBradley TaylorThomas McFallMandana KamgarWilliam A. HallBeth EricksonKathleen K. ChristiansDouglas B. EvansSusan Tsai

translational bioinformaticsprecision medicinegastrointestinal oncologygastroenterologyimmunologyhepatologydigestive diseasespancreatic ductal adenocarcinomacancer researchmedicinepersonalized medicinetranscriptomics technologyhealth sciencesoncologycancer biology

Atm or Chek2 Alterations as Potential Biomarkers of Improved Outcomes With Irinotecan: Real-World Analysis of Advanced Pancreatic Ductal Adenocarcinoma. (2023)

Mandana KamgarMaahum MehdiBicky ThapaAniko SzaboGulrayz AhmedAditya ShreenivasJames P. ThomasDeepika SriramDouglas B. EvansSusan TsaiKathleen K. ChristiansBeth EricksonWilliam A. HallHui-Zi ChenNikki LytleThomas McFallNavonil De SarkarSteve PatrickBen GeorgeRazelle Kurzrock

epidemiologymicroarray data analysisimmunologytumor biologyoutcomes researchcancer researchbiomarkershealth sciencesoncogenesprognostic biomarkersmedicinal researchreal-world analysismolecular cancercancer riskclinical evidenceimproved outcomesenzyme inhibitioncancer genomicsoncologypotential biomarkers

Data From Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. (2023)

Rayna RosatiLisa PolinCharles DuckerJing LiXun BaoDakshnamurthy SelvakumarSeongho KimBesa XhabijaMartha LarsenThomas McFallYanfang HuangBenjamin L. KidderAndrew FribleyJanice SaxtonHiroki KakutaPeter ShawManohar Ratnam

tumor-selective disruptionandrogen receptor functioncancer discoverytumor biologycancer researchoncogenesradiation oncologyendocrine oncologyendocrine disruptorsmedicinal researchmolecular cancerprostate cancerpathway analysisurologyneurologymetastasistumor targetingleukemiacancer genomicsoncology

Atm or Chek2 Alterations: Potential Biomarkers of Improved Outcomes With Irinotecan-Containing Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.. Journal of Clinical Oncology (2023)

Maahum MehdiBicky ThapaAniko SzaboGulrayz AhmedAditya V. ShreenivasJames P. ThomasDeepika SriramDouglas B. EvansSusan TsaiKathleen K. ChristiansBeth EricksonWilliam A. HallThomas McFallSteve PatrickBen GeorgeRazelle KurzrockMandana Kamgar

gynecologic oncologypathologycarcinogenesischemoprevention strategiescancer discoveryvascular biologytumor biologycancer researchpancreatic cancermolecular biologyoncogenesgastrointestinal oncologymedicinal researchirinotecan-containing chemotherapybiostatisticstumor targetingoncologyimproved outcomesclinical researchtherapeutic efficacypotential biomarkers

Co-Targeting Kras G12C and Egfr Reduces Both Mutant and Wild-Type Ras-Gtp. npj Precision Oncology (2022)

Thomas McFallMichael TrogdonAnita C. GuizarJohn F. LangenheimLaura Sisk-HackworthEdward C. Stites

drug targetingpharmacologygeneticsmutagenesis (molecular biology technique)cancer immunotherapycancer researchtumor suppressorsoncogenesgene therapyradiation oncologywild-type ras-gtpmedicinal researchcellular therapycancer careclinical radiation oncologytumor targetingenzyme inhibitioncancer genomicsoncology

1
2
3
4
10 / page

Thomas McFall

Assistant Professor

Medical College of Wisconsin

Affiliations

Biochemistry

Graduate School

Pancreatic Cancer Program

Thomas Mcfall is currently serving as a Biochemistry Assistant Professor at Medical College of Wisconsin.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Thomas McFall

Medical College of Wisconsin

Assistant Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract B008: Ex-Vivo Organotypic Tumor Model of Metastatic Core Biopsy Serve as a Pragmatic Platform for Real-Time Personalized Therapy in Pancreatic Adenocarcinoma. Cancer Research (2025)

Mathematical Modeling Suggests 14-3-3 Proteins Modulate Raf Paradoxical Activation. PLoS Computational Biology (2025)

molecular and cellular biologyprotein sciencecell signalingprotein functionmolecular cell biologymolecular biologybiological chemistrybiomolecular interactionssignal transduction14-3-3 proteins

Mek Inhibitor-Based Therapy in Metastatic Pancreatic Adenocarcinoma With Kras G12R Alteration.. Journal of Clinical Oncology (2025)

Pancreatic Cells Are Resistant to Krasq61L Expression Due to Hyperactive Erk/Mapk Signaling and Apoptosis Induction. Cancer Research Communications (2025)

Chemotherapy-Free Treatment Targeting Fusions and Driver Mutations in Kras Wild-Type Pancreatic Ductal Adenocarcinoma, a Case Series. Therapeutic Advances in Medical Oncology (2024)

chemotherapy-free treatmentpancreatic cancermedicinedriver mutationsoncology

Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Gastroenterology (2024)

Atm or Chek2 Alterations as Potential Biomarkers of Improved Outcomes With Irinotecan: Real-World Analysis of Advanced Pancreatic Ductal Adenocarcinoma. (2023)

Data From Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. (2023)

Atm or Chek2 Alterations: Potential Biomarkers of Improved Outcomes With Irinotecan-Containing Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.. Journal of Clinical Oncology (2023)

Co-Targeting Kras G12C and Egfr Reduces Both Mutant and Wild-Type Ras-Gtp. npj Precision Oncology (2022)

Thomas McFallMichael TrogdonAnita C. GuizarJohn F. LangenheimLaura Sisk-HackworthEdward C. Stites

1
2
3
4
10 / page

Similar Faculty Members

Brian Rowan

Institution

Tulane University

cancer letter

health science

Ratna K Vadlamudi

Institution

University of Texas Health Science Center at San Antonio

molecular cancer

estrogen signaling

Steffi Oesterreich

Institution

University of Pittsburgh

cancer letter

pathology

Muthusamy Thangaraju

Institution

Augusta University

stem cell research

breast cancer

Powel H Brown

Institution

Baylor College of Medicine

breast cancer

oncogene

Ramzi Mohammad

Institution

Wayne State University

translational research

oncogene

Seema Singh

Institution

University of South Alabama

molecular cancer

cancer growth

Evan Keller

Institution

University of Michigan

prostate cancer

urology

Frank Mccormick

Institution

University of California, San Francisco

signaling pathway

cancer cell

Rachel Schiff

Institution

Baylor College of Medicine

correlative biomarkers

breast cancer

Similar Faculty Members

Brian Rowan

Institution

Tulane University

cancer letter

health science

Ratna K Vadlamudi

Institution

University of Texas Health Science Center at San Antonio

molecular cancer

estrogen signaling

Steffi Oesterreich

Institution

University of Pittsburgh

cancer letter

pathology

Muthusamy Thangaraju

Institution

Augusta University

stem cell research

breast cancer

Powel H Brown

Institution

Baylor College of Medicine

breast cancer

oncogene

Ramzi Mohammad

Institution

Wayne State University

translational research

oncogene

Seema Singh

Institution

University of South Alabama

molecular cancer

cancer growth

Evan Keller

Institution

University of Michigan

prostate cancer

urology

Frank Mccormick

Institution

University of California, San Francisco

signaling pathway

cancer cell

Rachel Schiff

Institution

Baylor College of Medicine

correlative biomarkers

breast cancer